2.38
Edesa Biotech Inc Borsa (EDSA) Ultime notizie
What drives Edesa Biotech Inc. stock priceFree Advanced Stock Screener Access - PrintWeekIndia
Is Edesa Biotech Inc. a good long term investmentHigh-yield market plays - PrintWeekIndia
What analysts say about Edesa Biotech Inc. stockAccelerated profit realization - PrintWeekIndia
Edesa Biotech Inc. Stock Analysis and ForecastConsistent double returns - jammulinksnews.com
Edesa Biotech Insiders May Regret Not Buying More, Market Cap Hits US$16m - simplywall.st
What makes Edesa Biotech Inc. stock price move sharplyElite Stock Shortlist - Newser
How Edesa Biotech Inc. stock performs during market volatilityGrowth Stock Monitor - Newser
Why Edesa Biotech Inc. stock attracts strong analyst attentionMomentum Swing Watchlist - Newser
Edesa Biotech's JUST BREATHE Study Advances ARDS Treatment with Promising Progress - AInvest
Edesa Biotech Advances ARDS Treatment with JUST BREATHE Study - TipRanks
Edesa Biotech (NASDAQ:EDSA) Shares Down 1% – Here’s Why - Defense World
H.C. Wainwright Maintains Edesa Biotech(EDSA.US) With Buy Rating, Maintains Target Price $5 - 富途牛牛
Edesa Biotech secures up to C$23 million in funding under the Federal Government’s Strategic Innovation Fund for pivotal clinical study - Fasken
Edesa Biotech, Inc. closes US$10 million bought deal offering of common shares - Fasken
Edesa Biotech completes US$15 million private placement - Fasken
40,944 Shares in Edesa Biotech, Inc. (NASDAQ:EDSA) Bought by Citadel Advisors LLC - Defense World
Edesa Biotech Shareholders Approve Key Proposals at AGM - TipRanks
Edesa Biotech (EDSA) Receives Buy Rating from Lucid Capital | ED - GuruFocus
Zacks Small Cap Reduces Earnings Estimates for Edesa Biotech - Defense World
EDSA: Advancing EB06 for the Treatment of Vitiligo - Research Tree
EDSA: Advancing EB06 for the Treatment of Vitiligo… - Yahoo Finance
Positive Signs As Multiple Insiders Buy Edesa Biotech Stock - Yahoo Finance
Edesa Biotech Reports Fiscal 2nd Quarter 2025 Results - GlobeNewswire
Edesa Biotech Shifts Focus to Vitiligo Treatment in Q2 2025 - TipRanks
Edesa Biotech Q2 EPS USD -0.3 - marketscreener.com
Edesa Biotech Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Edesa Biotech Reports Q2 2025 Financial Results and Advances Vitiligo Drug Development Efforts - Nasdaq
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):